MX2013006595A - Tratamiento de lesion de la medula espinal y lesion traumatica del cerebro empleando celulas madre placentarias. - Google Patents

Tratamiento de lesion de la medula espinal y lesion traumatica del cerebro empleando celulas madre placentarias.

Info

Publication number
MX2013006595A
MX2013006595A MX2013006595A MX2013006595A MX2013006595A MX 2013006595 A MX2013006595 A MX 2013006595A MX 2013006595 A MX2013006595 A MX 2013006595A MX 2013006595 A MX2013006595 A MX 2013006595A MX 2013006595 A MX2013006595 A MX 2013006595A
Authority
MX
Mexico
Prior art keywords
injury
stem cells
treatment
spinal cord
traumatic brain
Prior art date
Application number
MX2013006595A
Other languages
English (en)
Spanish (es)
Inventor
Kristen Labazzo
James W Edinger
Stewart Abbot
Eric Law
Vladimir Jankovic
Aleksandar Francki
Aleksandr Kaplunovsky
Bitao Laing
Robert Hariri
Original Assignee
Anthrogenesis Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anthrogenesis Corp filed Critical Anthrogenesis Corp
Publication of MX2013006595A publication Critical patent/MX2013006595A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
MX2013006595A 2010-12-17 2011-12-15 Tratamiento de lesion de la medula espinal y lesion traumatica del cerebro empleando celulas madre placentarias. MX2013006595A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061424559P 2010-12-17 2010-12-17
PCT/US2011/065170 WO2012083024A1 (en) 2010-12-17 2011-12-15 Treatment of spinal cord injury and traumatic brain injury using placental stem cells

Publications (1)

Publication Number Publication Date
MX2013006595A true MX2013006595A (es) 2014-04-07

Family

ID=46234728

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013006595A MX2013006595A (es) 2010-12-17 2011-12-15 Tratamiento de lesion de la medula espinal y lesion traumatica del cerebro empleando celulas madre placentarias.

Country Status (9)

Country Link
US (1) US20120156230A1 (https=)
EP (1) EP2651451A4 (https=)
JP (1) JP2014507390A (https=)
KR (7) KR20180100251A (https=)
CN (1) CN103501822A (https=)
AU (1) AU2011343739A1 (https=)
CA (1) CA2821818A1 (https=)
MX (1) MX2013006595A (https=)
WO (1) WO2012083024A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2666503T3 (es) * 2012-05-16 2018-05-04 Becton, Dickinson And Company Características distintivas de superficie celular para aislar neuronas de cultivos celulares derivados de células madre pluripotentes
EP2863927A4 (en) * 2012-06-26 2015-12-02 Rusty Property Holdings Pty Ltd COMPOSITIONS AND METHODS FOR REDUCING THE FREQUENCY AND / OR INTENSITY OF THE CEPHALA
WO2014022427A1 (en) * 2012-08-02 2014-02-06 Bioaxone Biosciences Inc. Inhibition of rho and or rock and cell transplantation
US20160120909A1 (en) * 2013-05-10 2016-05-05 Cell-Innovations Ip Pty Ltd Compositions And Methods For The Treatment Of Tinnitus
US10058572B2 (en) * 2013-08-15 2018-08-28 The Regents Of The University Of California Placenta-derived multipotent stem cells
BR112016029624A2 (pt) 2014-06-18 2017-10-24 Csl Behring Gmbh terapia usando um inibidor do fator xii em um distúrbio neurotraumático
US10493105B2 (en) * 2014-09-11 2019-12-03 Taiwan Mitochondrion Applied Technology Co., Ltd Isolated adipose-derived mesenchymal stem cells treated with angelica extract or butylidenephthalide, and wherein the cells have an increased mitochondrial membrane potential and a decreased level of IL-8, and methods for treating parkinson's disease
GB201518263D0 (en) * 2015-10-15 2015-12-02 Oxford Bioelectronics Ltd Method
EP3423070B1 (en) * 2016-03-03 2022-05-04 Henry Ford Health System 3-d collagen scaffold-generated exosomes and uses thereof
EA201991371A1 (ru) * 2016-12-05 2019-12-30 Селулэрити, Инк. Лечение лимфедемы и связанных состояний с использованием плацентарных адгезивных клеток
US20200246386A1 (en) * 2017-04-24 2020-08-06 Pluristem Ltd. Methods and compositions for treating neurological disorders
US20180322956A1 (en) * 2017-05-05 2018-11-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Time Window-Based Platform for the Rapid Stratification of Blunt Trauma Patients into Distinct Outcome Cohorts
TW201910511A (zh) 2017-05-30 2019-03-16 美商維泰克斯製藥公司 C3融合蛋白以及其製備及使用方法
CN107227521B (zh) * 2017-08-09 2023-03-14 青岛金汇丰机械有限公司 一种五轴毛纺粗纱机
KR20190048894A (ko) 2017-10-31 2019-05-09 경상대학교산학협력단 Jnk 활성 억제제를 유효성분으로 포함하는 퇴행성 신경질환의 예방 또는 치료용 약학적 조성물
CN108413478A (zh) * 2018-02-11 2018-08-17 广东美的环境电器制造有限公司 一种控制方法、装置及计算机可读存储介质
KR102070403B1 (ko) 2019-09-06 2020-01-28 경상대학교 산학협력단 Jnk 활성 억제제를 유효성분으로 포함하는 외상성 뇌손상의 치료용 약학적 조성물
CN114561355B (zh) * 2022-01-23 2023-04-11 四川大学华西医院 一种脊髓瘢痕组织细胞急性快速分离方法
CN117274869B (zh) * 2023-09-25 2024-03-26 北方工业大学 一种基于形变场提取的细胞形变动态分类方法及系统

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080152629A1 (en) * 2000-12-06 2008-06-26 James Edinger Placental stem cell populations
US7311905B2 (en) * 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
PL2471907T3 (pl) * 2005-12-29 2019-07-31 Celularity, Inc. Populacje komórek macierzystych łożyska
WO2008036374A2 (en) * 2006-09-21 2008-03-27 Medistem Laboratories, Inc. Allogeneic stem cell transplants in non-conditioned recipients
NZ612888A (en) * 2007-02-12 2015-02-27 Anthrogenesis Corp Treatment of inflammatory diseases using placental stem cells
US20090214484A1 (en) * 2008-02-22 2009-08-27 Nikolay Mironov Stem cell therapy for the treatment of central nervous system disorders
CA2734237C (en) * 2008-08-20 2019-07-02 Anthrogenesis Corporation Treatment of stroke using isolated placental cells
RU2015130665A (ru) * 2008-11-19 2018-12-24 Антродженезис Корпорейшн Амниотические адгезивные клетки

Also Published As

Publication number Publication date
EP2651451A4 (en) 2014-05-21
KR20230116964A (ko) 2023-08-04
KR20210107144A (ko) 2021-08-31
KR20190090882A (ko) 2019-08-02
KR20130128437A (ko) 2013-11-26
AU2011343739A1 (en) 2013-05-02
CN103501822A (zh) 2014-01-08
KR20220103812A (ko) 2022-07-22
EP2651451A1 (en) 2013-10-23
WO2012083024A1 (en) 2012-06-21
JP2014507390A (ja) 2014-03-27
KR20180100251A (ko) 2018-09-07
WO2012083024A8 (en) 2013-08-01
KR20200116546A (ko) 2020-10-12
CA2821818A1 (en) 2012-06-21
US20120156230A1 (en) 2012-06-21

Similar Documents

Publication Publication Date Title
MX2013006595A (es) Tratamiento de lesion de la medula espinal y lesion traumatica del cerebro empleando celulas madre placentarias.
MX2019001414A (es) Angiogenesis utilizando celulas madre placentarias.
MX2011007930A (es) Conjugados de insulina cristalina.
MY158992A (en) Forms of rifaximin and uses thereof
MX2015006491A (es) Composiciones bacterianas sinergicas y metodos de produccion y uso de las mismas.
AU2011328009A8 (en) Compounds and methods for treating pain
EP4324527A3 (en) Formulations of enzalutamide
SG178991A1 (en) Anti-gitr antibodies
MX2012011543A (es) Tratamiento de sarcoidosis empleando celulas madre placentarias.
MX2014011134A (es) Compuestos de carbamato y preparacion y uso de los mismos.
MX2013004061A (es) Analogos de ciclosporina.
IN2015DN02938A (https=)
MX356210B (es) Formulaciones de polimero acrilico.
MX2013003309A (es) Compuestos de benzamida sustituidos.
IN2014KN02620A (https=)
AU2010306870A8 (en) Reducing the risk of pathological effects of traumatic brain injury
WO2011047091A9 (en) Methods for treating traumatic brain injury
MX357166B (es) Anticuerpos que se unen a notum pectinacetilesterasa.
MX2013004062A (es) Analogos de ciclosporina.
WO2009120368A3 (en) Treatment of brain damage using umbilical cord blood cells
WO2012082942A3 (en) Neuropeptide analogs, compositions, and methods for treating pain
WO2012009640A3 (en) B cell depletion for central nervous system injuries and methods and uses thereof
HK1187257A (en) Treatment of spinal cord injury and traumatic brain injury using placental stem cells
HK1187250A (en) Treatment of spinal cord injury and traumatic brain injury using amnion derived adherent cells
WO2014191553A3 (en) Human plgf-2 for the prevention or treatment of heart failure